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Abstract Acute respiratory distress syndrome (ARDS)
is a heterogeneous syndrome that occurs as a result of
various risk factors, including either direct or indirect
lung injury, and systemic inflammation triggered also by
severe pneumonia (SP). SP-ARDS-associated morbidi-
ty and mortality remains high also due to the lack of
disease-specific biomarkers. The present study aimed
at identifying disease-specific biomarkers in SP or
SP-ARDS by integrating proteomic profiles of inflam-
matory mediators with clinical informatics. Plasma was
sampled from the healthy as controls or patients with SP
infected with bacteria or infection-associated SP-ARDS
on the day of admission, day 3, and day 7. About 15 or
52 cytokines showed significant difference between SP
and SP-ARDS patients with controls or 13 between SP-
ARDS with SP alone and controls, including bone mor-
phogenetic protein-15 (BMP-15), chemokine (C-X-C
motif) ligand 16 (CXCL16), chemokine (C-X-C motif)
receptor 3 (CXCR3), interleukin-6 (IL-6), protein
NOV homolog (NOV/CCN3), glypican 3, insulin-like
growth factor binding protein 4 (IGFBP-4), IL-5,
IL-5 R alpha, IL-22 BP, leptin, MIP-1d, and orexin B
with a significant correlation with Digital Evaluation
Score System (DESS) scores. ARDS patients with
overexpressed IL-6, CXCL16, or IGFBP-4 had signifi-
cantly longer hospital stay and higher incidence of sec-
ondary infection. We also found higher levels of those
mediators were associated with poor survival rates in
patients with lung cancer and involved in the process of
the epithelial mesenchymal transition of alveolar epithe-
lial cells. Our preliminary study suggested that integra-
tion of proteomic profiles with clinical informatics as
part of clinical bioinformatics is important to validate
and optimize disease-specific and disease-staged
biomarkers.
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Introduction
Adult respiratory distress syndrome (ARDS) is a life-
threatening condition manifested as non-cardiogenic
pulmonary edema, respiratory distress, and hypoxemia
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with a high mortality and morbidity in critically ill
patients and resulted from various processes that directly
or indirectly compromise the lung (Schneider and
Sweberg 2013). ARDS was defined as an acute inflam-
mation with neutrophil infiltration and lung epithelial
and/or endothelial cell dysfunction, associated with in-
fection (Grommes and Soehnlein 2011). The present
therapeutic strategies for ARDS including supportive
care, pharmacological treatments, or ventilator support
are still controversial, due to the complexity of ARDS
and lack of understanding ofmolecular mechanisms (De
Luca et al. 2012). ARDS is commonly caused by sepsis,
pneumonia, trauma, aspiration pneumonia, pancreatitis,
and other critical clinical conditions (Puneet et al. 2005).
Most of patients with severe pulmonary infection be-
come more susceptive to ARDS, have longer duration
of hospital stay, or have higher mortality. Infection-
associated ARDS is characterized by an uncontrolled
inflammatory response to a local or systemic insult,
compromising lung alveolar epithelial and endothelial
barriers, acute inflammation, edema, or injury. The con-
comitant clinical course and outcome of ARDS are
associated with the degree of systemic inflammation
(Lundberg et al. 2000), by which altered production of
cytokines and chemokines may occur among different
stages and severities of the disease. Clinical and epide-
miologic studies have suggested a strong association
between chronic infection, inflammation, and cancer
(Balkwill and Mantovani 2012). Local infections (e.g.,
pneumonia and tuberculosis) and inflammation often
occur in patients with lung cancer (Engels 2008).
The present study aims at investigating dynamic
differences of proteomic profiles between patients with
severe pneumonia (SP) or SP accompanied with ARDS
(SP-ARDS) on days 1, 3, and 7 after hospital admission,
as compared with healthy controls. We have developed
the protocol of disease-specific biomarker selection and
evaluation by integrating proteomic profiles of inflam-
matory mediators in pulmonary diseases, e.g., chronic
obstructive pulmonary disease, at different stages and
durations, with clinical informatics and phenotypes
(Chen et al. 2012b). The present study mainly focused
on plasma inflammatory mediators measured by anti-
body microarray, characterized the modes of dynamic
alterations in the disease, and selected disease-specific
biomarkers by correcting selected biomarkers with
Digital Evaluation Score System (DESS) of patients.
We also evaluated the potential values of selected bio-
markers in the prediction of survival rates, of which
higher levels of CXCL6, interleukin-6 (IL-6), or
insulin-like growth factor binding protein 4 (IGFBP-4)
in the circulation were correlated with poor prognosis in
patients with SP-ARDS.
Materials and methods
Patient population Three hundred patients were recruit-
ed in the study, of whom 70 patients with bacteria-
associated SP-ARDS, with bacteria-associated SP
alone, or healthy people as normal controls, separately,
were enrolled, as shown in Supplement Table 1. SP was
defined by Infectious Disease Society of America/
American Thoracic Society (Brown and Dean 2011;
Brown et al. 2009). The definition of ARDS was rec-
ommended by the Berlin definition in a university hos-
pital (Hernu et al. 2013; Koh 2014; Ranieri et al. 2012),
which facilitated easy nomination of patients with
ARDS for a randomized, perspective clinical study.
Patients with SP or SP-ARDS received corticosteroids,
antibiotics, or short-term use of neuromuscular blockade
at initial stage of mechanical ventilation and prone ven-
tilation in severe ARDS after blood sample collection
for about 7 days when the symptoms were improved
(Bellani et al. 2016). All subjects were given informed
consent, and the protocol was approved by the Medical
Ethics Committee of the First affiliated Hospital,
Wenzhou Medical University, China.
Sampling procedure Plasma samples were collected in-
travenously three times from patients with SP or SP-
ARDS or healthy controls on the day after the initial
diagnosis and the admission (day 1), day 3, and day 7
after the admission and the treatment. The aliquots of
plasma were collected in potassium-EDTA tubes, cen-
trifuged at 2000 rpm for 20 min, and then stored at
−80 °C until analyses.
Microarray assay An antibody-based membrane array
for measuring inflammatory factors (A Custom
Raybio® Human Inflammation Antibody Array kit)
was purchased from Raybiotech (Norcross, GA, USA)
with 507 selected inflammatory mediators. Each anti-
body was spotted in duplicate onto one membrane. The
antibody microarray consists of numerous affinity re-
agents arrayed on a solid surface, and proteins that bind
specific target proteins to unique locations on the array
are subsequently detected (MacBeath 2002). Briefly,
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membranes immobilized with capture antibodies were
blocked with 5 % bovine serum albumin/Tris-buffered
saline (TBS) for 1 h and then incubated with 1 ml
samples in tenfold dilution with 5 % bovine serum
albumin/TBS for 2 h at room temperature. Membranes
were then incubated individually or collectively with
biotin-conjugated antibodies, after extensive washes
with TBS/0.1 % Tween 20 and TBS thrice to remove
unbound proteins. Membranes were then incubated with
horseradish peroxidase-conjugated streptavidin at
2.5 pg/ml for 1 h at room temperature. Unbound mate-
rials were washed out with TBS/0.1 % Tween 20 and
TBS. Buffers C and D were then mixed and loaded onto
the membranes to cover the entire surface for 5 min.
Finally, spots were detected by exposing to Kodak X-
Omat radiographic film for 1 min for image. Each film
was scanned with Scanalyze software, and spots were
digitized into densities. The data were exported into
Microsoft Excel, and for each spot, the net density was
determined by subtracting the background density from
the total raw density. The relative spot density in each
membrane equals to [the average of inflammatory
mediator spot density− blank density] / [the average
of positive control density− blank density] × 100 %.
According to the protocol from the manufacturer, the
positive signals are used to identify the orientation and
compare the relative expression levels among the differ-
ent membranes. Horseradish peroxidase-conjugated an-
tibody served as a positive control as 12 spots and was
also used to identify the orientation. The positive control
of density in the microarray was the known protein in
the controlled concentration to control the quality of
sample load, the density of spots, and the operation.
DESS DESS is a score index to translate clinical
descriptions and information into clinical informat-
ics, which took into account patient symptoms,
signs, doctor examination, biochemical analyses, and
clinical imaging, as described previously (Chen et al.
2012a). Variables in the DESS included symptoms in
Supplement Table 2, signs in Supplement Table 3, and
clinical biochemical analysis in Supplement Table 4.
For the assessment of severity, each component was
then assigned with 0, 1, 2, and 4 as shown in
Supplement Tables 2–4. The score of 4 as the maximal
value indicates far more above normal range or much
severer condition, while 0 as the minimal value indicates
that it is within physiological range. Several variables
were 0 or 4, e.g., orthopnea at night, chill, three
depression signs, barrel chest, etc. The value of 3 was
missed in the scoring system for exponential values in
order to better define the severity stages. After compil-
ing patients’ data, the points of each variable were added
so that the DESS scores ranged from 0 to 264 points,
with higher scores indicating a severer condition.
Patients were scored on the day when plasma samples
were collected.
Gene function analyses All genes correspondent to
measured proteins were enrolled in further bioinformat-
ic analyses. We used GenCLip 2.0 (http://ci.smu.edu.cn/
GenCLiP2.0/analysis.php) for gene cluster analysis
(Huang et al. 2008) and Molecule Annotation System
(MAS 3.0) (http://bioinfo.capitalbio.com/mas3/) to
generate gene ontology (GO) gene function annotation.
Survival analyses Mediators, measured in patients with
SP-ARDS and demonstrated statistically significant as
compared with either those with SP alone or healthy
controls, were furthermore assayed in plasma and the
correlation with the survival rate in additional patients
with diseases from the hospital was evaluated (n=300).
Genes of selected specific proteins in patients with SP-
ARDS and correlated with the survival rate were further
analyzed for survival prediction values for patients with
lung cancer. Univariate associations between expression
profiles and survivals were assessed by Cox regression
using the coxph function from the R statistical software
package Bsurvival.^ Differences between survival
curves and log rank P values were assessed using the
survdiff function of the Bsurvival^ package. The nor-
malized RNA-seq data from 528 ADC samples and 532
SCC samples were obtained from Broad GDAC
FIREHOSE on 7 November 2013. In addition, the clin-
ical survival data were obtained from the Cancer
Genome Atlas (TCGA) FTP server (https://tcga-data.
nci.nih.gov/tcgafiles/ftp_auth/distro_ftpusers/
anonymous/tumour) on 6 December 2013. These data
were used to build survival models. Besides, another
online survival prediction database including 1715 non-
small cell lung cancer samples of ten independent
datasets was also used to build survival models
(Gyorffy et al. 2013).
Epi the l i a l mesenchymal t rans i t i on (EMT)
measurement A549 cells were cultured with 5, 50 , or
500 ng/ml IL-6 in six-well plate (×105 cells/well) for
48 h. Total RNA was isolated using a guanidinium
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isothiocyanate/chloroform-based technique (TRIzol,
Invitrogen, USA) and measured with OD 260 nm.
RNA was subsequently reversed and transcribed to
cDNA with the SuperScript First-Strand Synthesis
System (Invitrogen, USA). Quantitative RT-PCR was
carried out using an ABI 7000 PCR instrument
(Eppendorf, Hamburg, Germany) with the two-stage
program parameters, as follows: 1 min at 95 °C
and then 40 cycles of 5 s at 95 °C and 30 s at
60 °C. The sequences of the primer sets used for




(F) and 5′-ACCAGAGGGAGTGAATCCAGA-3′ (R);
and for human glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH), 5′-CCACCCATGGCAAATTCCA
TGGCA-3 ′ (F) and 5 ′ -TCTACACGGCAGG
TCAGGTCCACC-3′ (R). Specificity of the produced
amplification product was confirmed by examination of
dissociation reaction plots. Each sample was tested in
triplicate with quantitative RT-PCR, and each group had
six wells.
Western blot analysis Intracellular protein was extracted
by radio immunoprecipitation assay lysis buffer 48 h
after IL-6 stimulation. Protein samples (50 μg) were
mixed with an equal volume of 5× sodium dodecyl
sulfate buffer, boiled for 5 min, and then separated
through 10 % sodium dodecyl sulfate-polyacrylamide
gel electrophoresis gels. After electrophoresis, proteins
were transferred to polyvinylidene fluoride membranes
by electrophoretic transfer. Membranes were blocked in
5 % dry milk for 2 h, rinsed, and incubated with primary
antibodies (diluted at their instructions) in TBS thrice at
4 °C overnight. Primary antibody was then removed by
washing in TBS and labeled by incubating with 0.1 mg/
ml peroxidase-labeled secondary antibodies (against
mouse and rabbit) for 2 h. Following three washes in
TBS, bands were visualized by ECL and exposed to X-
ray film. All results were calculated by Phoretix 1D
software.
Statistical analysis Statistical analysis were performed
by SPSS software (SPSS 18.0; SPSS Inc., Chicago, IL).
Signal densities of microarrays among the three groups
were analyzed with one-way ANOVA, followed by an
unpaired Student’s t test to compare the difference be-
tween two groups, when the ANOVA test indicated
significance. The subset of mediators with signifi-
cance among groups was then selected. Correlation
analysis between total DESS and selected mediator
intensities was performed by the nonparametric
Spearman correlation test. All data were expressed
as mean ± SEM, and a P value of <0.05 was con-
sidered statistically significant.
Results
Thirty-six DESS variables of patients with SP-ARDS on
day 1 were significantly higher than those on days 3 and
7 as listed in Table 1, and 28 variables in patients with
SP on day 3 were significantly higher than those on days
1 and 7 (Table 1). DESS scores represented the severity
of patients and declined as the condition improved. Total
DESS values in SP-ARDS patients were 544, 339, or
285 on post-admission 1, 3, or 7 days, respectively, and
DESS values on day 1 were significantly higher than on
days 3 and 7 (Table 2; P<0.01, respectively). While
total DESS values in SP patients were 274, 410, or 250
on post-admission 1, 3, or 7 days, respectively, and
DESS values on day 3 were significantly higher than
days 1 and 7 (Table 3; P<0.05, respectively).
Levels of inflammatory mediators in patients with SP
were significantly altered on day 3, as compared with
controls, consistent with the DESS scores as shown in
Table 3. SP patients had similar alterations of
inflammation-associated proteins, e.g., insulin-like
growth factor I receptor (IGF-I sR), insulin-like growth
factor II (IGF-II), lipopolysaccharide-binding protein
(LBP), or leukocyte cell-derived chemotaxin 2
(LECT2), to SP-ARDS patients. C-C motif ligand 21
(6Ckine), lipopolysaccharide receptor (CD14),
interleukin-1 receptor 4 (IL-1 R4/ST2), insulin-like
growth factor binding protein 2 (IGFBP-2), insulin-
like growth factor I (IGF-I), and defensin-beta1 (BD-1)
were significantly changed in SP patients, as compared
with healthy controls or SP-ARDS patients at corre-
sponding days.
Thirteen inflammatory mediators in SP-ARDS pa-
tients showed significant difference from healthy con-
trols or SP patients, including bone morphogenetic
protein-15 (BMP-15), chemokine (C-X-C motif) ligand
16 (CXCL16), chemokine (C-X-C motif) receptor 3
(CXCR3), IL-6, protein NOV homolog (NOV/CCN3),
glypican 3, IGFBP-4, IL-5, IL-5 receptor alpha (IL-
5Rα), IL-22 binding protein (IL-22BP), leptin,
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macrophage inflammatory protein-1d (MIP-1d), and
orexin B. Among them, clinical informatics, such as
symptoms, signs, laboratory tests, and imaging, had
significant correlation with those 13 different proteins
listed in Supplement Tables 5–8.
Levels of IL-6, IL-5Rα, CXCR3, or CXCL16 in
patients with SP-ARDS on day 3 were significantly
higher than those in SP patients or controls and in SP
alone higher than in controls (Fig. 1, P<0.05 or 0.01,
respectively). Levels of IL-6, IL-5Rα, CXCR3,
Table 1 Variables for seven ALI/ARDS and five severe pneumonia (SP) patients on days 1, 3, and 7 (mean± SEM)
Variables Day 1 Day 3 Day 7
ARDS SP ARDS SP ARDS SP
Cough severity 0.857 ± 0.34 1.17± 0.43 0 3.21± 0.691 0 1.211 ± 0.632
Sputum 2.286 ± 0.644 1.572 ± 0.584 1.429 ± 0.683 3.337 ± 0.884 1.286 ± 0.583 1.299 ± 0.631
Shortness of breath 2.714 ± 0.474 0.564 ± 0.347 1.286 ± 0.36 1.286 ± 0.36 0.857 ± 0.404 0
Limitation of activity 3.429 ± 0.369 0 2.143 ± 0.553 0.932 ± 0.411 2 ± 0.577 0
Chill 2.286 ± 0.808 0 0 1.043 ± 0.436 0 0
Fever (°C) 1.714 ± 0.644 1.378 ± 0.524 0.857 ± 0.143 1.921 ± 0.684 0 0
Appetite 2.143 ± 0.705 0.843 ± 0.662 1 ± 0.378 1.893 ± 0.618 0.714 ± 0.286 0.997 ± 0.583
Stool and urine 1.143 ± 0.738 0 0 1.214 ± 0.594 0 0
Temperature (°C) 2.286 ± 0.474 1.686 ± 0.872 1 ± 0.378 2.495 ± 0.773 0.286 ± 0.184 1.186 ± 0.564
Heart rate (beat/min) 3.429 ± 0.571 1.413 ± 0.654 1.714 ± 0.808 1.714 ± 0.808 1.714 ± 0.808 0
Respiratory rate (min) 2.571 ± 0.528 1.267 ± 0.634 1.143 ± 0.595 1.943 ± 0.664 0.857 ± 0.34 0
Blood pressure (mmHg) 1 ± 0.309 0 0.286 ± 0.184 0.763 ± 0.127 0.143 ± 0.143 0
Barrel chest 1.714 ± 0.808 0.571 ± 0.571 0.571 ± 0.571
Chest palpitation 1.714 ± 0.808 0.736 ± 0.408 0 1.694 ± 0.512 0 0
Chest percussion 3.429 ± 0.571 0 1.143 ± 0.738 0.971 ± 0.369 1.333 ± 0.843 0
Rales 2 ± 0.577 1.774 ± 0.5769 1 ± 0.378 3.125 ± 0.878 0.714 ± 0.36 1.462 ± 0.579
WBC (×109/L) 2.857 ± 0.738 1.818 ± 0.697 1.571 ± 0.481 2.171 ± 0.583 1.143 ± 0.508 1.512 ± 0.508
Neutrophil percentage (%) 3.429 ± 0.571 1.729 ± 0.851 1.629 ± 0.528 2.743 ± 0.828 1 ± 0.535 1.242 ± 0.535
Albumin (g/L) 2.571 ± 0.469 1.143 ± 0.595 1.714 ± 0.68
ALT (U/L) 2.286 ± 0.606 1.143 ± 0.738 0.571 ± 0.571
AST (U/L) 2.036 ± 0.714 1.286 ± 0.521 1.132 ± 0.734
ALP (U/L) 2.286 ± 0.606 1.143 ± 0.738 0.571 ± 0.571
Urea (mmol/L) 2.857 ± 0.595 0 1.286 ± 0.644 1.166 ± 0.574 1 ± 0.378 0
HDL (mmol/L) 1.429 ± 0.685 0.143 ± 0.143 0
Na (mmol/L) 0.429 ± 0.202 0.143 ± 0.143 0.843 ± 0.137 0
K (mmol/L) 1.857 ± 0.769 1.186 ± 0.508 0.286 ± 0.184 1.798 ± 0.614 0.286 ± 0.184 0
Cl (mmol/L) 2.286 ± 0.808 0.571 ± 0.571 0.571 ± 0.571
Ca (mmol/L) 0.571 ± 1.512 0 0
pH 1.714 ± 1.808 1.623 ± 0.708 0.571 ± 0.571 1.771 ± 0.614 0.571 ± 0.571 0.571 ± 0.571
PaO2 (mmHg) 1 ± 0.218 1.312 ± 0.514 0.429 ± 0.202 2.129 ± 0773 0.286 ± 0.184 1.486 ± 0.594
PaCO2 (mmHg) 2.859 ± 0.952 1.783 ± 0.652 1.383 ± 0.718 2.113± 0.917 1.714 ± 0.808 1.524 ± 0.714
SaO2 (%) 1.571 ± 0.218 1.157 ± 0.418 0.829 ± 0.534 1.932 ± 0.589 0.429 ± 0.535 0.919 ± 0.417
C-reactive protein, CRP (mg/L) 3.143 ± 0.404 2.243 ± 0.804 1.286 ± 0.565 1.986 ± 0.992 0.857 ± 0.459 0.857 ± 0.338
Lung consolidation 2.167 ± 0.654 1.476 ± 0.558 0.833 ± 0.307 1.833 ± 0.344 0.5 ± 0.224 1.105 ± 0.667
Pleural effusion 1.5 ± 0.563 1.605 ± 0.821 0.756 ± 0.27 1.997 ± 0.693 0.333 ± 0.221 1.023 ± 0.775
Emphysema 2.667 ± 0.843 1.787 ± 0.615 1.333 ± 0.769 1.923 ± 0.801 0.667 ± 0.667 1.206 ± 0.657
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CXCL16, NOV/CCN3, MIP-1d, or BMP-15 in patients
with SP-ARDS increased significantly from day 1 and
on and remained significantly higher during the hospital
stay, as compared with both SP alone or controls. Levels
of BMP-15, IGFBP-4, glypican 3, IL-22BP, IL-5, leptin,
or orexin B in SP-ARDS patients gradually and signif-
icantly increased by time as compared with the previous
day and from day 1 or day 3 and on as compared with
controls or SP alone (Figs. 1 and 2, P<0.05 or less,
respectively). Levels of 6Ckine and IGFBP-2 or
IL-1R4/ST2 in SP patients were significantly higher
from day 1 or day 3 and on as compared with those in
controls and in SP-ARDS patients, as shown in Fig. 2
(P<0.05 or less). Figure 3 demonstrated that levels of
IGF-I sR, IGF-II, LBP, LECT2, CD14, IGF-I, or BD-1
increased in both SP and SP-ARDS patients from day 1
and on, as compared with controls.
Gene clusters associated with CC chemokine recep-
tors, draining lymph nodes, monocyte chemotactic pro-
teins, cell surfaces, cell migrations, cell differentiations,
tumor necrosis factor, or immune responses significant-
ly up-expressed in SP-ARDS patients (Fig. 4a). Ten
most frequent GO terms were selected for GO biological
process and molecular function analysis in the present
study. The GO biological processes of up-expressed
genes mainly included immune response, monocyte
chemotaxis, negative regulation of chemokine biosyn-
thesis, neutrophil apoptosis, hepatic immune response,
IL-6-mediated signaling pathway, negative regulation of
collagen biosynthetic process, inflammatory response,
positive regulation of peptidyl-tyrosine phosphoryla-
tion, and chemotaxis in SP-ARDS patients (Fig. 4b).
In GO molecular function, genes related with signal
transducer activity, receptor activity, G protein-coupled
receptor activity, heparin binding, scavenger receptor
activity, chemokine receptor activity, low-density
lipoprotein receptor activity, C-X-C chemokine re-
ceptor activity, chemoattractant activity, IL-6 re-
ceptor binding, IL-5 receptor binding, cytokine
activity, and chemokine activity up-expressed in
SP-ARDS patients (Fig. 4c).
We further measured mRNA expression of selected
13 ARDS-specific inflammatory mediators in circulat-
ing leukocytes of 200 patients with ARDS and found
that ARDS patients with higher expression of IL-6,
CXCL16, or IGFBP-4 had longer hospital stay
(18.6 ± 4.3 vs 9.3 ± 3.2 days) and higher incidence
of secondary infection (36.5±6.2 vs 12.4±3.6 %), re-
spectively. We also found that the expression of IL-6,
CXCL16, or IGFBP-4 significantly predicted the poor
overall survival in patients with lung cancer (Fig. 4d–f).
Of those, IL-6 was one of the strongest poor prognosis
Table 2 Scores of seven ALI/ARDS patients on each day when
samples were collected
ALI/ARDS-1 ALI/ARDS-3 ALI/ARDS-7
Patient 1 74 35 57
Patient 2 57 42 19
Patient 3 76 47 50
Patient 4 103 75 60
Patient 5 82 26 31
Patient 6 77 54 27
Patient 7 75 60 41
Total scores 544 339 285
Mean 77.71428571 48.42857143 40.71428571
SEM 5.144179724 6.167723756 5.931009252
No, 7 7 7
P 0.001760105 0.000265417
P 0.192531293
Table 3 Scores of five severe pneumonia patients on each day







Patient 1 24 61 37
Patient 2 55 100 38
Patient 3 91 94 81
Patient 4 60 85 74
Patient 5 44 70 20
Total scores 274 410 250
Mean 54.8 82 50
SEM 10.96083938 7.286974681 11.7260394
No. 5 5 5
P 0.038926513 0.386280889
P 0.027623376
Fig. 1 Plasma levels of IL-6, CXCL16, CXCR3, MIP-1d, NOV/
CCN3, IL-5 R alpha, BMP-15, and IL-22BP in healthy and
patients with SP or ARDS on days 1, 3, and 7. Single letter x
and double letter x stand for P values less than 0.05 and 0.01,
respectively, as compared with healthy controls. Single plus sign
and double plus sign stand for P values less than 0.05 and 0.01,
respectively, as compared with SP patients. Single number sign
and double number sign stand for P values less than 0.05 and 0.01,
as compared with ARDS patients on day 1
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predictors. Furthermore, we found higher levels of those
mediators were involved in the process of the EMT of
alveolar epithelial cells. To characterize whether IL-6 is
capable of inducing an EMT phenotype to promote lung
cancer, we investigated the gene and protein expression
of the epithelial marker E-cadherin and the mesenchy-
mal marker vimentin and found an expression pattern of
E-cadherin repression (Fig. 5a) and concomitant
induction of vimentin (Fig. 5b) in lung cancer
cells as compared with control cells. To further
study the effects of IL-6 on A549 cells, we de-
tected EMT phenotype protein by western blot and
found that the expression of E-cadherin was sig-
nificantly decreased 48 h after IL-6 administration
at 50 or 500 ng/ml (Fig. 5c). The expression of
vimentin significantly increased with IL-6 at 50 ng/ml
for 48 h in A549 cells and even more significantly
increased at 500 ng/ml (Fig. 5d).
Discussion
Inflammation plays an important role in the pathogene-
sis of ARDS, a severe form of acute lung injury, char-
acterized by the activation of leukocytes, dysfunction of
the endothelial and epithelial barrier, leakage of a
protein-rich exudate from the circulation to the alveolar
space and interstitial tissues, or lung injury and disability
of gas exchange (Shields et al. 2002). Overactivated
leukocytes, endothelial cells, and/or epithelial cells
could produce and release a large number of inflamma-
tory mediators, responsible for the initiation and accel-
eration of the secondary inflammatory reactions (Wang
et al. 2007). A panel of altered systemic biomarkers may
provide more and deeper understanding of the patho-
genesis, monitor the development of the disease and
responses to therapies, and identify optimal therapies
or personalized medicine, since the single mediator
could not reflect the complex of the inflammation in
ARDS.
The present study explored systemic profiles of in-
flammatory mediators among SP patients with or with-
out ARDS at difficult disease stages and severities by
integrating clinical informatics and bioinformatics and
understanding the biological function and signal net-
works, in order to identify the disease-specific bio-
markers and develop preventive, diagnostic, and predic-
tive methods for personalized medicine as summarized
in Fig. 6. It was highly recommend that validated bio-
markers based on clinical proteomics should be integrat-
ed with medical imaging with clinical care, personalized
treatment paradigms to reduce mortality, and healthcare
costs of the diseases (Kato et al. 2011). An integrative
systems biology research strategy could overcome lim-
itations in identifying functional and regulatory path-
ways (Auffray et al. 2010) and predicting multi-scale
models ranging from the molecule to the organ levels.
The present study investigated networks of selected
ARDS-specific inflammatory mediators, e.g., BMP-15,
CXCL16, CXCR3, IL-6, NOV/CCN3, glypican 3,
IGFBP-4, IL-5, IL-5 R alpha, IL-22 BP, leptin, MIP-
1d, or orexin B, and suggested disease-specific bio-
markers as explained in Supplement Figs. 1–11.
Infection-induced SP is one of common and critical
pathogeneses in the development of ARDS (Soma
2013). The present study was designed to identify 13
dynamic biomarkers of SP-ARDS, different from the
healthy or SP patients alone. The severity of the disease
was reflected by variations of BMP-15, glypican 3,
IGFBP-4, IL-5, IL-22 BP, leptin, or orexin B between
day 1 and day 7 of ARDS patients, while the represen-
tative of SP was defined by the differentiation from the
healthy and ARDS patients (e.g., 6Ckine, CD14, IL-1
R4 /ST2, IGFBP-2, IGF-I, or BD-1), which may be
useful for early diagnosis and monitoring for SP pa-
tients. In addition, some inflammation-associated pro-
teins (e.g., IGF-I sR, IGF-II, LBP, and LECT2) had
similar alterations in ALI/ARDS and SP patients, which
will be regarded as an index of evaluation for patients
with inflammation, such as routine blood test. Our data
from the present study also indicate that the activated
cell migration and immune response occurred in SP-
ARDS patients, including the gene cluster of CC che-
mokine receptor, monocyte chemotactic protein, cell
migration, or immune response, biological process of
immune response, monocyte chemotaxis, inflammatory
response, or chemotaxis, and molecule function of che-
mokine receptor activity, chemoattractant activity, cyto-
kine activity, and chemokine activity.
Fig. 2 Plasma levels of IGFBP-4, glypican 3, IL-5, leptin (OB),
orexin B, IGFBP-2, IL-1 R4/ST2, and 6Ckine in healthy and
patients with SP or ARDS on days 1, 3, and 7. Single letter x
and double letter x stand for P values less than 0.05 and 0.01,
respectively, as compared with healthy controls. Single plus sign
and double plus sign stand for P values less than 0.05 and 0.01,
respectively, as compared with SP patients. Single number sign
and double number sign stand for P values less than 0.05 and 0.01,
as compared with ARDS patients on day 1
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Our data demonstrate that elevated levels of certain
inflammatory mediators during SP-ARDS may be po-
tential risk factors for the initiation of lung cancer. IL-6
plays an essential role and has the specificity to regulate
the nature of inflammation in lung cancer microenviron-
ment and has tumor-promoting actions (Ochoa et al.
2011). Clinical findings demonstrated that levels
of IL-6 increased in the circulation and regional
fluids were associated with poor prognosis of pa-
tients with malignant diseases (Uskudar Teke et al.
2015), and the antibody against IL-6 siltuximab
could inhibit the phosphorylation of STAT3 tyro-
sine and cell growth in NSCLC (Song et al. 2011).
Results from our data mining furthermore found
that the up-expression of IL-6 could predict poor
prognosis predictors in NSCLC and that IL-6 is
also involved in the signal pathway of cell prolif-
eration (Supplement Fig. 1). To better explore the
potential association and interaction mechanisms
between IL-6 and EMT in lung cancer cells, we
stimulated A549 with IL-6 in vitro cell culture.
Our data initially demonstrated that the expression
of IL-6 is associated with EMT. It indicates that
IL-6 may also regulate the process of EMT during
the progression of NSCLC, by which cells change from
a highly polarized epithelial phenotype with intact cell–
cell junctions to a migratory mesenchymal phenotype to
promote tumor cell metastasis (Sullivan et al. 2009).
Molecular mechanisms by which selected disease-
specific biomarkers may contribute to the development
of ARDS aswell as tumorigenesis of lung cancer mainly
include alterations of cell motility (CXCR3, Supplement
Fig. 2), cytokine production, cell adhesion or differenti-
ation (IL-5, IL-5 R alpha, Supplement Fig. 3), survival
and migration (CXCL16, Supplement Fig. 4), metabo-
lism (leptin or orexin B, Supplement Fig. 5 or 6), or cell
proliferation and adhesion (NOV/CCN3 or IGFBP-4,
Supplement Fig. 7 or 8). Those factors are involved in
the multi-processes of lung inflammation, injury, or
tumorigenesis, e.g., IL-22 BP in Supplement Fig. 9 or
glypican in Supplement Fig. 10, and associated with the
inflammation (Supplement Fig. 11).
To better characterize disease-specific biomarkers, it
needs to even test a large number of potential protein
biomarkers. The disease specificity of those multiple
cytokines requires the comparison among many lung
diseases, particularly like ARDS that results from a
complex process of initiation and progression of inflam-
mation network. The present study specially focused on
dynamic alterations of systemic biomarkers in patients
with SP-ARDS. Simultaneous detection of multiple cy-
tokines as a panel will provide a more powerful tool to
quantifiably measure cytokines in different stages of
ARDS, like in other diseases (Chen et al. 2012a).
However, because of the limitations in available sample
volume and cost, it is difficult to obtain results of many
proteins from ELISA measurement. Additionally, the
challenges were also encountered during the identifica-
tion and validation, such as large variation of results,
concentrations of peptides and proteins (Rose et al.
2004), or the specificity of serum proteins (Chen et al.
2010). Of many omics technologies, antibody microar-
ray provides an opportunity to take insight into global
protein expression profiles (Huang 2001) and may be
used to detect multiple proteins from one sample in an
accurate, reproducible, and rapid manner as a fast,
high-throughput, and sensitive tool for identifying
potential biomarkers and in detecting levels of plasma
cytokines.
Another challenge is how to integrate genomic or
proteomic data with clinical characteristics and directly
benefit the patients (Marshall 2011). The existing score
index, such as the BODE index (Celli et al. 2004), has
been used to monitor and provide good predictive infor-
mation in a clinical practice, while they are graded with
only partial variables that are not adequate for high-
throughput analysis. Thus, there is an urgent need to
combine advanced proteomic biotechnologies, clinical
proteomics, tissue imaging and profiling, and organ
dysfunction score systems together, to improve the clin-
ical outcomes of patients (Wang et al. 2006). We devel-
oped a new systemDESS to translate clinical descriptive
information on major symptoms, signs, biochemical
analyses, and imaging into clinical informatics as the
digital values, to integrate the clinical informatics with
bioinformatics, and to correlate molecular measurement
with clinical direct vision for physicians and shrink the
distance between lab discovery and clinical condition.
Our data from the present study indicates that the digital
informatics of those selected clinical parameters was
correlated with disease-specific biomarkers. We found
Fig. 3 Plasma levels of IGF-I sR, IGF-II, LBP, BD-1, LECT2,
CD14, and IGF-I in healthy and patients with SP or ARDS on days
1, 3, and 7. Single letter x and double letter x stand for P
values less than 0.05 and 0.01, respectively, as compared
with healthy controls. Single plus sign and double plus sign
stand for P values less than 0.05 and 0.01, respectively, as
compared with SP patients
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that plasma levels of inflammatory mediators were
watched with severities of clinical informatics at various
stages of the disease and that the multi-factorial scoring
system could be useful when assessing and monitoring
Fig. 4 The alterations of gene clusters (a), biological processes (b), and molecular function (c) in ARDS patients. The poor overall survival
rate in patients with lung cancer predicted by selected genes CXCL16 (d), IL-6 (e), and IGFBP-4 (f)
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outcomes in ARDS patients. However, there are impor-
tant needs to test a large population of patients with SP
or ARDS, even though it is a challenge due to the cost of
microarray, the limit of patient number for the recruit-
ment, and large amount of works on clinical informatics.
It should be also pointed out that the amount measured
Fig. 5 IL-6 promotes a gene expression pattern and phenotype
consistent with EMT. A549 cells were treated with 5, 50, or
500 ng/ml IL-6 for 24 h. Real-time quantitative PCR analysis of
A549 cells showed a robust decrease in E-cadherin gene expres-
sion (a) and concomitant increase in vimentin (b). Western blot
analysis of A549 showed the expressions of E-cadherin were
significantly decreased (c) and vimentin was up-regulated (d) after
48 h stimulated by IL-6. Each data point represents mean ± SEM
of three experiments. Single letter x and double letter x stand for P
values less than 0.05 and 0.01, in comparison with untreated
control cells
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in the present study is the part of inflammatory media-
tors. The microarray used in the present study provided
the information on relative folds of changes, rather than
exact amount of circulating proteins. The correla-
tion in the density of the spots for a particular
protein with disease status may not necessarily
mean that protein is directly involved in the dis-
ease process. In addition, it would be more helpful
if there is a mathematical model to correlate
proteomic-based bioinformatics with clinical infor-
matics, so bioinformatics can be interpreted into clin-
ical prediction and monitoring with the computational
assistance. The efficiency of DESS used in the present
study for clinical bioinformatics needs to be furthermore
evaluated in the future.
In conclusion, we explored the feasibility and reli-
ability of a new protocol of disease-specific biomarker
evaluation by integrating proteomic profiles of inflam-
matory mediators in different ARDS stages, with clini-
cal informatics. We measured 507 plasma inflammatory
mediators and found 13 ARDS-specific biomarker can-
didates in patients different from both healthy and SP
patients. We also explored the correction between
selected biomarkers with DESS scores of patients to
understand potential link of proteomic profile with clin-
ical findings. There is a need to validate the predictive
capability of those mediators in a large population of
patients and clarify their specificity to ARDS as com-
pared with levels in other pulmonary diseases and de-
velop a simple and practical method which could serve
as an aid in clinical practice and in the context of ARDS
research.
Acknowledgments The work was supported by Shanghai Lead-
ing Academic Discipline Project (B115), Zhongshan Distin-
guished Professor Grant (XDW), The National Nature Science
Foundation of China (91230204, 81270099, 81320108001,
81270131, 81400035, 81570075, 81500058, 81500025), The
Shanghai Committee of Science and Technology (12JC1402200,
12431900207, 11410708600), Zhejiang Provincial Natural Sci-
ence Foundation (Z15H010002), and Zhejiang Provincial Science
Technology Department Foundation (WKJ-ZJ-1526).
Author contributions Shuanying Yang and Xiangdong Wang
conceived and designed the study. Chengshui Chen and Lin Shi
performed the biological experiments. Yuping Li and Lin Shi
analyzed the statistical data. Chengshui Chen and Lin Shi wrote
the paper. All authors read and proofread the final manuscript.
Fig. 6 Workflow of the present study. As a new protocol of
biomarker evaluation and development, it is achieved by compar-
ing systemic profiles of inflammatory mediators among different
study groups, integrating clinical informatics and bioinformatics,
and understanding the biological function and signal networks.
Clinical informatics is generated through a new DESS, while
circulating inflammatory mediators are measured by the antibody
array and followed by proteomic-based bioinformatics. Disease-
specific biomarkers are identified by integrating clinical informat-
ics and functional networks through the global proteomic data set,
in order to develop preventive, diagnostic, and predictive methods
for personalized medicine
182 Cell Biol Toxicol (2016) 32:169–184
Compliance with ethical standards
Competing interests The authors declare that they have no
competing interests.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestrict-
ed use, distribution, and reproduction in any medium, provided
you give appropriate credit to the original author(s) and the source,
provide a link to the Creative Commons license, and indicate if
changes were made.
References
Auffray C, Adcock IM, Chung KF, Djukanovic R, Pison C, Sterk
PJ. An integrative systems biology approach to understand-
ing pulmonary diseases. Chest. 2010;137(6):1410–6.
Balkwill FR, Mantovani A. Cancer-related inflammation: com-
mon themes and therapeutic opportunities. Semin Cancer
Biol. 2012;22(1):33–40.
Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, et al.
Epidemiology, patterns of care, and mortality for patients
with acute respiratory distress syndrome in intensive care
units in 50 countries. JAMA: J Am Med Assoc.
2016;315(8):788–800.
Brown SM, Dean NC. Defining severe pneumonia. Clin Chest
Med. 2011;32(3):469–79.
Brown SM, Jones BE, Jephson AR, Dean NC. Validation of the
Infectious Disease Society of America/American Thoracic
Society 2007 guidelines for severe community-acquired
pneumonia. Crit Care Med. 2009;37(12):3010–6.
Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca
M, Mendez RA, et al. The body-mass index, airflow
obstruction, dyspnea, and exercise capacity index in
chronic obstructive pulmonary disease. N Engl J Med.
2004;350(10):1005–12.
Chen H, Wang D, Bai C, Wang X. Proteomics-based biomarkers
in chronic obstructive pulmonary disease. J Proteome Res.
2010;9(6):2798–808.
Chen H, Song Z, Qian M, Bai C, Wang X. Selection of
disease-specific biomarkers by integrating inflammatory
mediators with clinical informatics in AECOPD patients:
a preliminary study. J Cell Mol Med. 2012a;16(6):1286–
97.
Chen H, Wang Y, Bai C, Wang X. Alterations of plasma inflam-
matory biomarkers in the healthy and chronic obstructive
pulmonary disease patients with or without acute exacerba-
tion. J Proteome. 2012b;75(10):2835–43.
De Luca D, Piastra M, Tosi F, Pulitano S, Mancino A, Genovese
O, et al. Pharmacological therapies for pediatric and neonatal
ALI/ARDS: an evidence-based review. Curr Drug Targets.
2012;13(7):906–16.
Engels EA. Inflammation in the development of lung cancer:
epidemiological evidence. Expert Rev Anticancer Ther.
2008;8(4):605–15.
Grommes J, Soehnlein O. Contribution of neutrophils to acute
lung injury. Mol Med. 2011;17(3-4):293–307.
Gyorffy B, Surowiak P, Budczies J, Lanczky A. Online
survival analysis software to assess the prognostic
value of biomarkers using transcriptomic data in
non-small-cell lung cancer. PLoS One. 2013;8(12):
e82241.
Hernu R, Wallet F, Thiolliere F, Martin O, Richard JC, Schmitt Z,
et al. An attempt to validate the modification of the
American-European consensus definition of acute lung
injury/acute respiratory distress syndrome by the Berlin def-
inition in a university hospital. Intensive Care Med.
2013;39(12):2161–70.
Huang RP. Detection of multiple proteins in an antibody-based
protein microarray system. J ImmunolMethods. 2001;255(1-
2):1–13.
Huang ZX, Tian HY, Hu ZF, Zhou YB, Zhao J, Yao KT.
GenCLiP: a software program for clustering gene lists by
literature profiling and constructing gene co-occurrence
ne tworks r e l a t ed to cus tom keywords . BMC
Bioinformatics. 2008;9:308.
Kato H, Nishimura T, Ikeda N, Yamada T, Kondo T, Saijo N, et al.
Developments for a growing Japanese patient population:
facilitating new technologies for future health care. J
Proteome. 2011;74(6):759–64.
Koh Y. Update in acute respiratory distress syndrome. J Intensive
Care. 2014;2(1):2.
Lundberg AH, Granger DN, Russell J, Sabek O, Henry J, Gaber L,
et al. Quantitative measurement of P- and E-selectin adhesion
molecules in acute pancreatitis: correlation with distant organ
injury. Ann Surg. 2000;231(2):213–22.
MacBeath G. Protein microarrays and proteomics. Nat Genet.
2002;32(Suppl):526–32.
Marshall E. Human genome 10th anniversary. Waiting for the
revolution. Science. 2011;331(6017):526–9.
Ochoa CE, Mirabolfathinejad SG, Ruiz VA, Evans SE, Gagea M,
Evans CM, et al. Interleukin 6, but not T helper 2 cytokines,
promotes lung carcinogenesis. Cancer Prev Res (Phila).
2011;4(1):51–64.
Puneet P, Moochhala S, Bhatia M. Chemokines in acute respira-
tory distress syndrome. Am J Physiol Lung Cell Mol Physiol.
2005;288(1):L3–15.
Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND,
Caldwell E, Fan E, et al. Acute respiratory distress
syndrome: the Berlin Definition. JAMA: J Am Med
Assoc. 2012;307(23):2526–33.
Rose K, Bougueleret L, Baussant T, BohmG, Botti P, Colinge J, et al.
Industrial-scale proteomics: from liters of plasma to chemically
synthesized proteins. Proteomics. 2004;4(7):2125–50.
Schneider J, Sweberg T. Acute respiratory failure. Crit Care Clin.
2013;29(2):167–83.
Shields CJ, Winter DC, Redmond HP. Lung injury in acute pan-
creatitis: mechanisms, prevention, and therapy. Curr Opin
Crit Care. 2002;8(2):158–63.
Soma K. Acute respiratory distress syndrome and pneumonia.
Masui Jpn J Anesthesiol. 2013;62(5):547–56.
Song L, Rawal B, Nemeth JA, Haura EB. JAK1 activates STAT3
activity in non-small-cell lung cancer cells and IL-6 neutral-
izing antibodies can suppress JAK1-STAT3 signaling. Mol
Cancer Ther. 2011;10(3):481–94.
Sullivan NJ, Sasser AK, Axel AE, Vesuna F, Raman V, Ramirez
N, et al. Interleukin-6 induces an epithelial-mesenchymal
Cell Biol Toxicol (2016) 32:169–184 183
transition phenotype in human breast cancer cells. Oncogene.
2009;28(33):2940–7.
Uskudar Teke H, Gunduz E, Akay OM, Bal C, Gulbas Z. Are the
high serum interleukin-6 and vascular endothelial growth
factor levels useful prognostic markers in aggressive non-
Hodgkin lymphoma patients? Turk J Haematol: Off J Turk
Soc Haematol. 2015;32(1):21–8.
Wang X, Adler KB, Chaudry IH, Ward PA. Better understanding
of organ dysfunction requires proteomic involvement. J
Proteome Res. 2006;5(5):1060–2.
Wang X, Adler KB, Erjefalt J, Bai C. Airway epithelial dysfunc-
tion in the development of acute lung injury and acute respi-
ratory distress syndrome. Expert Rev Respir Med. 2007;1(1):
149–55.
184 Cell Biol Toxicol (2016) 32:169–184
